Endometrial Endometrioid Adenocarcinoma

Endometrial Endometrioid Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

42 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 20
Recruiting: 8
Ph III recruiting: 2
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05538897	Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers	active not recruiting	Phase 1 / Phase 2	96	National Cancer Institute (NCI)NIH	1	Jul 27, 2026	clinicaltrials
NCT03120624	VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer	active not recruiting	Phase 1	34	Mayo ClinicOTHER	1	Jul 21, 2026